{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:40:39Z","timestamp":1771461639563,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902754"],"award-info":[{"award-number":["81902754"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,3,23]]},"DOI":"10.1038\/s41416-022-02090-0","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T19:13:59Z","timestamp":1670094839000},"page":"833-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["IL-33\/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma"],"prefix":"10.1038","volume":"128","author":[{"given":"Mengxiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijia","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-5470","authenticated-orcid":false,"given":"Zhiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-3884","authenticated-orcid":false,"given":"Yanhong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-0923","authenticated-orcid":false,"given":"Liang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"2090_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"2090_CR2","doi-asserted-by":"publisher","first-page":"104460","DOI":"10.1016\/j.oraloncology.2019.104460","volume":"99","author":"JD Cramer","year":"2019","unstructured":"Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol. 2019;99:104460.","journal-title":"Oral Oncol"},{"key":"2090_CR3","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1084\/jem.20161462","volume":"213","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835\u201340.","journal-title":"J Exp Med"},{"key":"2090_CR4","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529.","journal-title":"BMJ"},{"key":"2090_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22:836\u201347.","journal-title":"Lancet Oncol"},{"key":"2090_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer. 2018;17:129.","journal-title":"Mol Cancer"},{"key":"2090_CR7","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, et al. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin Cancer Res. 2018;24:4579\u201387.","journal-title":"Clin Cancer Res"},{"key":"2090_CR8","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","volume":"26","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, et al. Tumor mutational burden and PTEn alterations as molecular correlates of response to PD-1\/L1 blockade in metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2565\u201372.","journal-title":"Clin Cancer Res"},{"key":"2090_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.molcel.2021.01.010","volume":"81","author":"M Yu","year":"2021","unstructured":"Yu M, Peng Z, Qin M, Liu Y, Wang J, Zhang C, et al. Interferon-gamma induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation. Mol Cell. 2021;81:1216\u201330.e1219.","journal-title":"Mol Cell"},{"key":"2090_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u201368.","journal-title":"Cancer Lett"},{"key":"2090_CR11","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/onc.2017.188","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene. 2017;36:5829\u201339.","journal-title":"Oncogene"},{"key":"2090_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"2090_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390.","journal-title":"J Exp Med"},{"key":"2090_CR14","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2090_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/carcin\/bgy006","volume":"39","author":"L Ding","year":"2018","unstructured":"Ding L, Ren J, Zhang D, Li Y, Huang X, Hu Q, et al. A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF\/interleukin-33. Carcinogenesis. 2018;39:397\u2013406.","journal-title":"Carcinogenesis"},{"key":"2090_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.ajpath.2019.12.007","volume":"190","author":"X Zhao","year":"2020","unstructured":"Zhao X, Ding L, Lu Z, Huang X, Jing Y, Yang Y, et al. Diminished CD68(+) cancer-associated fibroblast subset induces regulatory T-cell (Treg) infiltration and predicts poor prognosis of oral squamous cell carcinoma patients. Am J Pathol. 2020;190:886\u201399.","journal-title":"Am J Pathol"},{"key":"2090_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-019-1277-x","volume":"38","author":"Y Wang","year":"2019","unstructured":"Wang Y, Jing Y, Ding L, Zhang X, Song Y, Chen S, et al. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway. J Exp Clin cancer Res: CR. 2019;38:274.","journal-title":"J Exp Clin cancer Res: CR"},{"key":"2090_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1535-7163.MCT-16-0454","volume":"16","author":"L Ding","year":"2017","unstructured":"Ding L, Ren J, Zhang D, Li Y, Huang X, Ji J, et al. The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects. Mol Cancer Ther. 2017;16:1068\u201379.","journal-title":"Mol Cancer Ther"},{"key":"2090_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12619","volume":"281","author":"C Cayrol","year":"2018","unstructured":"Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281:154\u201368.","journal-title":"Immunol Rev"},{"key":"2090_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1158\/2326-6066.CIR-19-0828","volume":"8","author":"J Son","year":"2020","unstructured":"Son J, Cho JW, Park HJ, Moon J, Park S, Lee H, et al. Tumor-infiltrating regulatory T-cell accumulation in the tumor microenvironment is mediated by IL33\/ST2 signaling. Cancer Immunol Res. 2020;8:1393\u2013406.","journal-title":"Cancer Immunol Res"},{"key":"2090_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00262-018-2265-2","volume":"68","author":"YH Wen","year":"2019","unstructured":"Wen YH, Lin HQ, Li H, Zhao Y, Lui VWY, Chen L, et al. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis. Cancer Immunol Immunother. 2019;68:221\u201332.","journal-title":"Cancer Immunol Immunother"},{"key":"2090_CR22","doi-asserted-by":"publisher","first-page":"687430","DOI":"10.3389\/fonc.2021.687430","volume":"11","author":"Z Ding","year":"2021","unstructured":"Ding Z, He Y, Fu Y, Zhu N, Zhao M, Song Y, et al. CD38 multi-functionality in oral squamous cell carcinoma: prognostic implications, immune balance, and immune checkpoint. Front Oncol. 2021;11:687430.","journal-title":"Front Oncol"},{"key":"2090_CR23","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"2090_CR24","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.4049\/jimmunol.1800447","volume":"202","author":"B Griesenauer","year":"2019","unstructured":"Griesenauer B, Jiang H, Yang J, Zhang J, Ramadan AM, Egbosiuba J, et al. ST2\/MyD88 deficiency protects mice against acute graft-versus-host disease and spares regulatory T cells. J Immunol. 2019;202:3053\u201364.","journal-title":"J Immunol"},{"key":"2090_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","volume":"8","author":"B Griesenauer","year":"2017","unstructured":"Griesenauer B, Paczesny S. The ST2\/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475.","journal-title":"Front Immunol"},{"key":"2090_CR26","doi-asserted-by":"publisher","first-page":"e20191054","DOI":"10.1084\/jem.20191054","volume":"218","author":"L Wang","year":"2021","unstructured":"Wang L, Luo Y, Luo L, Wu D, Ding X, Zheng H, et al. Adiponectin restrains ILC2 activation by AMPK-mediated feedback inhibition of IL-33 signaling. J Exp Med. 2021;218:e20191054.","journal-title":"J Exp Med"},{"key":"2090_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/jir.2006.26.53","volume":"26","author":"KA Shirey","year":"2006","unstructured":"Shirey KA, Jung JY, Maeder GS, Carlin JM. Upregulation of IFN-gamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. J Interferon Cytokine Res. 2006;26:53\u201362.","journal-title":"J Interferon Cytokine Res"},{"key":"2090_CR28","doi-asserted-by":"publisher","first-page":"100411","DOI":"10.1016\/j.xcrm.2021.100411","volume":"2","author":"S Liu","year":"2021","unstructured":"Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, et al. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep. Med. 2021;2:100411.","journal-title":"Cell Rep. Med"},{"key":"2090_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, Muller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Disco. 2020;10:232\u201353.","journal-title":"Cancer Disco"},{"key":"2090_CR30","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","volume":"27","author":"PM Galbo Jr","year":"2021","unstructured":"Galbo PM Jr, Zang X, Zheng D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 2021;27:2636\u201347.","journal-title":"Clin Cancer Res"},{"key":"2090_CR31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/cancers11091257","volume":"11","author":"C Inoue","year":"2019","unstructured":"Inoue C, Miki Y, Saito R, Hata S, Abe J, Sato I, et al. PD-L1 induction by cancer-associated fibroblast-derived factors in lung adenocarcinoma cells. Cancers (Basel). 2019;11:1257.","journal-title":"Cancers (Basel)"},{"key":"2090_CR32","doi-asserted-by":"publisher","first-page":"152884","DOI":"10.1016\/j.prp.2020.152884","volume":"216","author":"M Zhang","year":"2020","unstructured":"Zhang M, Shi R, Guo Z, He J. Cancer-associated fibroblasts promote cell growth by activating ERK5\/PD-L1 signaling axis in colorectal cancer. Pathol Res Pract. 2020;216:152884.","journal-title":"Pathol Res Pract"},{"key":"2090_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hep.32099","volume":"75","author":"Y Lin","year":"2022","unstructured":"Lin Y, Cai Q, Chen Y, Shi T, Liu W, Mao L, et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology. 2022;75:28\u201342.","journal-title":"Hepatology"},{"key":"2090_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1073-4","volume":"18","author":"S Peng","year":"2019","unstructured":"Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18:165.","journal-title":"Mol Cancer"},{"key":"2090_CR35","doi-asserted-by":"publisher","first-page":"610923","DOI":"10.3389\/fonc.2020.610923","volume":"10","author":"Y Guo","year":"2020","unstructured":"Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, et al. Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review. Front Oncol. 2020;10:610923.","journal-title":"Front Oncol"},{"key":"2090_CR36","doi-asserted-by":"publisher","first-page":"e65614","DOI":"10.7554\/eLife.65614","volume":"10","author":"JT Clark","year":"2021","unstructured":"Clark JT, Christian DA, Gullicksrud JA, Perry JA, Park J, Jacquet M, et al. IL-33 promotes innate lymphoid cell-dependent IFN-gamma production required for innate immunity to Toxoplasma gondii. Elife 2021;10:e65614.","journal-title":"Elife"},{"key":"2090_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41590-019-0555-2","volume":"21","author":"A Hatzioannou","year":"2020","unstructured":"Hatzioannou A, Banos A, Sakelaropoulos T, Fedonidis C, Vidali MS, Kohne M, et al. An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion. Nat Immunol. 2020;21:75\u201385.","journal-title":"Nat Immunol"},{"key":"2090_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cyto.2017.07.022","volume":"99","author":"SH Park","year":"2017","unstructured":"Park SH, Kim MS, Lim HX, Cho D, Kim TS. IL-33-matured dendritic cells promote Th17 cell responses via IL-1beta and IL-6. Cytokine. 2017;99:106\u201313.","journal-title":"Cytokine"},{"key":"2090_CR39","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.4049\/jimmunol.1502702","volume":"197","author":"S Ganesan","year":"2016","unstructured":"Ganesan S, Pham D, Jing Y, Farazuddin M, Hudy MH, Unger B, et al. TLR2 activation limits rhinovirus-stimulated CXCL-10 by attenuating IRAK-1-dependent IL-33 receptor signaling in human Bronchial epithelial cells. J Immunol. 2016;197:2409\u201320.","journal-title":"J Immunol"},{"key":"2090_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479\u201390.","journal-title":"Immunity"},{"key":"2090_CR41","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/blood-2009-02-203372","volume":"114","author":"YS Choi","year":"2009","unstructured":"Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2\/TRAF6-mediated endothelial nitric oxide production. Blood. 2009;114:3117\u201326.","journal-title":"Blood"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02090-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:06:01Z","timestamp":1677715561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02090-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,23]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02090-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval for this study including tumor biopsy and serum collection was obtained from the Research Ethics Committee of Nanjing Stomatology Hospital (No.2019NL-009(KS)) and informed consent was obtained from the patients. The study was performed in accordance with the Declaration of Helsinki. All animal experiments were performed in accordance with Jiangsu Association for Laboratory Animal Science (Authorization Number: 220195073) and were subject to review by the animal welfare and ethical review board of Nanjing university.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}